title: Monoclonal antibodies conjugated with radioisotopes for the treatment of Non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  To describe the use of monoclonal antibodies labeled with iodine-131 tositumomab and yttrium-90 ibritumomab-tiuxetan as treatment for non-Hodgkin's lymphoma.
  
  
  METHODS
  Literature review of trials of radioimmunotherapy.
  
  
  CONCLUSIONS
  Radiolabeled monoclonal antibodies recognize and react with specific antigens to provide targeted therapy to tumor cells, particularly hematopoietic tumor cells. This therapy delivers greater amounts of radiation to malignant cells than normal cells and spares critical organs that do not express the antigen. Strict safety and patient precautions must be in place with the use of radiotherapy.
  
  
  CONCLUSIONS
  As the use of radiommunotherapy in the treatment of non-Hodgkin's lymphoma grows, the role of nursing in the care of these patients will also grow. Nurses will play an important part in patient and family education, as well as staff preparation.
authors.affiliation: Division of Medical Oncology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave East, G6800, Seattle, WA 98109, USA.
authors.forename: Sherri
authors.initials: S
authors.lastname: Bush
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000451:nursing / Q000532:radiotherapy*; D008657:Metabolic Clearance Rate; D016499:Radioimmunotherapy / Q000379:methods* / Q000451:nursing
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C119496:tositumomab I-131